Establishment of quantitative RNAi-based forward genetics in *Entamoeba histolytica* and
identification of genes required for growth

Akhila Bettadapur¹, Samuel S. Hunter^{2*}, Rene L. Suleiman^{1*}, Maura C. Ruyechan¹, Wesley
Huang¹, Charles G. Barbieri³, Matthew L. Settles², and Katherine S. Ralston^{1#}

¹Department of Microbiology and Molecular Genetics, University of California, Davis, USA

²Genome Center, University of California, Davis, USA

³SeqMatic, LLC, Fremont, California, USA

*These authors contributed equally to this work

Running Head: Forward genetics and identification of genes required for *Entamoeba*
histolytica growth

#Address correspondence to Katherine S. Ralston, ksralston@ucdavis.edu

Author Contributions

A.B. designed and performed the experiments, except fragmentation of gDNA, immunofluorescence, and growth curves with expression of full-length or truncated proteins. R.L.S. performed immunofluorescence experiments. M.C.R. performed growth curves with expression of full-length or truncated proteins. W.H. generated transfectants expressing full-length SG2. C.G.B. fragmented gDNA and processed the fragments to enable subsequent plasmid library construction. S.S.H. designed the analysis strategy for Illumina sequencing data, and analyzed all Illumina sequencing data. M.L.S. oversaw the Illumina analysis approach. K.S.R. performed growth curves, conceived of the overall approach and oversaw the design and analysis of the experiments. A.B., S.S.H., and K.S.R. wrote the manuscript.

Abstract

While *Entamoeba histolytica* remains a globally important pathogen, it is dramatically understudied. The tractability of *E. histolytica* has historically been limited, which is largely due to challenging features of its genome. To enable forward genetics, we constructed and validated the first genome-wide *E. histolytica* RNAi knockdown mutant library. This library allows for Illumina deep sequencing analysis for quantitative identification of mutants that are enriched or depleted after selection. We developed a novel analysis pipeline to precisely define and quantify gene fragments. We used the library to perform the first RNAi screen in *E. histolytica* and identified slow growth (SG) mutants. Among genes targeted in SG mutants, many had annotated functions consistent with roles in cellular growth or metabolic pathways. Some targeted genes were annotated as hypothetical or lacked annotated domains, supporting the power of forward genetics in uncovering functional information that cannot be gleaned from databases. While the localization of neither of the proteins targeted in SG1 nor SG2 mutants could be predicted by sequence analysis, we showed experimentally that SG1 localized to the cytoplasm and cell surface, while SG2 localized to the cytoplasm. Overexpression of SG1 led to increased growth, while expression of a truncation mutant did not lead to increased growth, and thus aided in defining functional domains in this protein. Finally, in addition to establishing forward genetics, we uncovered new details of the unusual *E. histolytica* RNAi pathway. These studies dramatically improve the tractability of *E. histolytica* and open up the possibility of applying genetics to improve understanding of this important pathogen.

Author Summary

Entamoeba histolytica is a globally important pathogen that is dramatically understudied. One of the major limitations of this organism is its challenging genome. RNAi is the state-of-the-art tool for genetic manipulation in *E. histolytica*, though the RNAi pathway has several noncanonical features. Here, we harnessed the RNAi pathway to enable forward genetics for the first time in this organism. We validated the RNAi library by performing the first *E. histolytica* RNAi screen and identified slow growth mutants. We showed that independently-generated mutants also exhibited slow growth phenotypes, and we characterized protein localization and domains for some of the identified slow growth genes. The RNAi library that we constructed enables modern, quantitative Illumina deep sequencing analysis to identify mutants that are enriched or depleted after selection. We developed a novel analysis pipeline to precisely define and quantify full-length gene fragments inferred from read mapping. Our approach differs from previous approaches for analysis of RNAi screens, and it better represents the actual DNA fragments and their quantities. This study dramatically improves the tractability of this important pathogen. Moreover, the strategies behind this RNAi library, and its analysis, are novel, and can be applied to other organisms.

Introduction

Entamoeba histolytica is the causative agent of amoebiasis in humans. *E. histolytica* is common in developing nations and is responsible for ~50 million infections/year [1]. In an endemic area, approximately 80% of infants are infected with *E. histolytica* [2]. Malnutrition and stunting are associated with childhood *E. histolytica* infections [3]. In children enrolled in the Global Enteric Multicenter Study, *E. histolytica* infection was associated with the highest risk of death between enrollment and follow up [4]. Amoebiasis results in an estimated 15,500 deaths/year in children and 67,900 deaths/year in people of all ages [5]. There is no vaccine and therapy is limited to nitroimidazoles [6]. The continued morbidity and mortality indicate that current treatment and prevention approaches are insufficient.

Despite its impact on human health, *E. histolytica* is dramatically understudied relative to other parasites. The genome is relatively difficult to manipulate. *E. histolytica* is tetraploid [7]. The genome contains many expanded gene families, which comprise 56% of the proteome [8, 9]. The genome is ~75% A + T, which creates challenges for genomic approaches and has contributed to the relatively poor draft genome quality. The genome is ~20 Mb with ~8,000 genes [8, 10]. For one third of genes, no homologues have been identified [10] and less than half of genes have gene ontology (GO) terms [8]. Thus, with limited sequence homology information and a difficult genome, functional approaches such as forward genetics are needed to identify genes that are relevant to pathogenesis.

Historically, the genetic tractability of *E. histolytica* has been limited. Forward genetics have not yet been established in *E. histolytica*, outside of two studies that used a plasmid-based overexpression library to screen for phenotypes [11, 12]. More recently, the

endogenous RNAi pathway in *E. histolytica* has been characterized, and exploited as a useful tool for targeted gene knockdown.

The existence of an RNAi pathway in *E. histolytica* that could be exploited for gene knockdown was implied by an approach that knocked down expression of amoebapore A [13]. However, the mechanism was unclear, and the expression of off-target genes was affected [14, 15]. A clonal line of stable transfectants carrying the amoebapore A plasmid was named the “G3” strain, and was subsequently used to knockdown additional genes in the context of an amoebapore A knockdown mutant background [14]. Other strategies for gene knockdown have included expression of genes in the antisense orientation [16], expression of long double stranded RNA [17], phagocytosis of bacteria expressing dsRNA [18], and expression of short hairpin RNA [19]. These techniques have been useful for reverse genetic studies, but not robust enough to be effective for every gene of interest.

In later studies, the *E. histolytica* RNAi pathway was characterized in detail. Small RNAs were found to be 27nt in length and 5’ polyphosphorylated [20]. 5’ polyphosphorylated siRNAs have only been seen in *E. histolytica* and *Caenorhabditis elegans* [21]. Supporting that these small RNAs are relevant to previous approaches that exploited gene silencing in *E. histolytica*, in the G3 strain, 27nt small RNAs mapped to amoebapore A, and when additional genes were silenced in this background, new small RNAs mapped to the newly silenced gene [22]. There is no obvious Dicer homologue, but a potential noncanonical Dicer and Argonaute homologues have been characterized [23, 24].

Because endogenous small RNAs are polyphosphorylated, it was initially a challenge to exploit this pathway for gene knockdown. A major breakthrough was the discovery that

RNAi knockdown could be induced by spreading of silencing [25]. A new “trigger” plasmid approach was established, which relies on endogenous small RNAs directed to short fragment of an endogenously-silenced gene (called the trigger) to drive spreading of silencing to a fragment of gene of interest adjacent to the trigger [25]. This leads to long-term silencing of the gene of interest and the deposition of a repressive histone mark [26]. This approach has been successfully applied in many studies, and in *E. invadens* [27-29].

In other parasites, RNAi knockdown has been successfully adapted for forward genetic approaches, and this has been very effective in uncovering genes relevant to parasite metabolism [30, 31], DNA repair [32], virulence [33], transmission [34, 35], and drug therapies [36-39]. Initially, these approaches relied on the generation of clonal lines after selection, and Sanger sequencing analysis of individual clones to identify the knocked down gene [30, 31]. More recent studies used next generation sequencing on non-clonal mutant populations in order to identify mutants and quantify their relative abundance [32-39]. The latter approaches are useful because they can quantitatively identify mutants that are enriched by selection, and mutants that are less abundant or are lost after selection.

To enable forward genetics, we constructed and validated the first genome-wide *E. histolytica* RNAi knockdown mutant plasmid library. Its design allows for Illumina deep sequencing, and our novel analysis pipeline allows for quantitative identification of plasmids that are enriched or depleted after selection. Using a pilot version of the library, we performed the first RNAi screen in *E. histolytica* and identified slow growth mutants. These studies establish the first RNAi screen in *E. histolytica*, thereby dramatically improving the tractability of this pathogen.

Results

Approach for quantitative RNAi-based forward genetics

We devised an overall strategy for RNAi-based forward genetics in *E. histolytica* (Fig. 1). For this approach, a library of genes would be introduced into the *E. histolytica* “trigger” RNAi plasmid (pTrigger) [25], to create an RNAi library (Fig. 1a). Amoebae would then be stably-transfected with the library, and exposed to a selective pressure or screening strategy. Illumina deep sequencing analysis would then be used to sequence the inserts and to compare the selected mutants to control, non-selected amoebae, in order to identify mutants that are quantitatively enriched or depleted. We empirically determined that the stable transfection efficiency with the backbone of pTrigger is ~1/1000 amoebae. This relatively high stable transfection efficiency suggested that transfecting enough amoebae to achieve genome-wide RNAi knockdown would be feasible.

The Illumina priming sequences that are necessary for sequencing are typically added to samples by using a nested strategy with two sequential PCR reactions. We modified the trigger plasmid in order to flank the insert with Illumina adaptor sequences, creating pTriggerAdaptor, so that after extracting amoebic genomic DNA (gDNA), only a single PCR step would be needed to generate DNA ready for sequencing (Fig. 1b). Using fewer PCR reactions is expected to reduce the potential for PCR bias that can change the representation of sequences. An additional benefit of this modification is that the original sequences flanking the insert were A/T rich and were not optimal for primer design. The insertion of these Illumina sequences into the knockdown plasmid did not change knockdown efficacy (Fig. 1c).

Construction of a plasmid RNAi library

Building on these findings, we devised a strategy to construct a genome-wide plasmid RNAi library (Fig. 2a). We reasoned that since ~50% of the genome is coding, constructing a gDNA library would be a practical approach. To generate the plasmid library, random fragments of gDNA were inserted into the pTriggerAdaptor plasmid. Library construction was initially done on a small scale, to create a “pilot” library, where plasmids were harvested from a limited number of bacterial colonies. Building on the results of the pilot, a second library was constructed on a larger scale, to make a “final” library that was expected to have genome-wide coverage.

Previous studies defined that an insert size ≥ 500 bp is sufficient for knockdown [25, 40]. Larger insert sizes are likely to lead to more efficient knockdown, but fragments > 1 kb are problematic for Illumina sequencing. The pilot library was constructed using gDNA fragments between ~400 – 600 bp. Building on the robust Illumina sequencing results from the pilot library (described in detail below), we constructed the final library, where gDNA fragments were larger (between ~500 – 900 bp) in order to maximize the efficacy of RNAi knockdown.

To make the RNAi library, high quality, RNA-free, gDNA (Fig. S1a – b) was sonicated and size-selected (Fig. S1c). Y-shaped adaptors were ligated to the fragmented DNA to ensure that each fragment was flanked by sequences matching the trigger plasmid upstream and downstream of the cloning site, in order to enable subsequent Gibson cloning. Adaptor ligation was successful, with an appropriate size shift seen using bioanalyzer analysis (Fig. 2b – c). Gibson cloning and plasmid preps were done *en masse*

with pooled plasmids. To check cloning efficiency, individual colonies were obtained and analyzed. Restriction analysis demonstrated that the ligation efficiency was very high, since 63 out of 67 plasmids examined contained an insert (Fig. 2d).

The RNAi library has genome-wide coverage

Illumina sequencing was used to analyze the pilot and final libraries, and the fragmented gDNA that was used to construct each library. Notably, our approach for analysis of the sequencing data is novel and differs from previous approaches for analysis of RNAi screens [32-39] since all results presented here are based on full-length DNA-fragments inferred from read mapping results (Fig. S2), rather than on more traditional read mapping coverage or CDS overlap counting strategies. Our approach was designed to better represent the actual DNA fragments present in the plasmid library, instead of just the short ends of these fragments that were sequenced on the Illumina platform. This strategy allowed us to precisely define whether a fragment might target one or multiple genes, and enabled a clearer view of fragment based genome coverage. This approach will also allow us to readily quantify the representation of gene fragments in future RNAi screen experiments, in order to identify specific fragments that are particularly impactful in a particular screen.

There did not appear to be bias in gDNA fragmentation or construction of the library, since the nucleotide and dinucleotide frequencies of the fragmented gDNA and the plasmids were the same as the genome (Fig. 3a and S3a). Rarefaction curves and read fragment analysis showed that sequencing was performed to a sufficient depth to identify all unique fragments within the plasmid samples, but the same depth of sequencing was not

deep enough to identify all unique fragments within the fragmented gDNA samples (Fig. S3b – c).

Illumina sequencing analysis was performed on separate batches of the plasmid library that had been cloned on different days, and on technical sequencing replicates. Similar read counts per fragment were obtained from each batch and each sequencing replicate, showing that cloning and sequencing were reproducible and there was no evidence for bias within these steps (Fig. S4a – b, Table S1). Analysis of the sequencing results showed that the gDNA fragments that were used to create the pilot library had a mean size of 421 bp, and the fragments in the pilot plasmid library had a mean size of 427 bp (Fig. 3b). The gDNA fragments that were used to create the final library had a mean size of 540 bp, and the fragments in the pilot plasmid library had a mean size of 555 bp (Fig. 3b). The nearly identical size ranges of the gDNA fragments and cloned fragments further support that there was no bias during library construction.

Genome coverage plots of the final plasmid library over the 5 largest contigs in the genome visually showed that coverage of these contigs was complete, and the depth of coverage was consistent (Fig. 3c). The breadth and depth of coverage over a zoomed in region of the largest contig is represented in Fig. 3d. On a genome-wide level, the genome was well covered by fragments that were cloned into the library in both the forward and reverse orientation relative to the orientation of coding sequences (Fig. 4, Table 1). Supporting that the final library contained genome-wide coverage, 97.24% of the genome was represented (Table 1). 8307 of 8333 annotated genes were represented, and the majority (8301 genes) were represented by more than one unique fragment. Of the 26

genes that are missing, 22 are likely to be misannotated in the genome, since they were not seen in any sample, including fragmented gDNA (Fig. S5). Additionally, for the majority of these genes, there was no empirical evidence for gene expression in prior RNAseq or proteomic studies (Tables S2 and S3). From these findings, we concluded that the final plasmid library has genome-wide coverage. We named the final library pEhKDL, since it represents an *E. histolytica* knockdown library.

Forward genetic isolation of slow growing mutants

While the final library was under construction, *E. histolytica* was stably transfected with the pilot library. To determine if the RNAi library could be used to identify genes that contribute to a phenotype, we screened for mutants with abnormal growth. To first ask how many different plasmids were present per stably transfected amoeba, clonal lines were obtained using limiting dilution. Sanger sequencing analysis of clonal lines was consistent with only one unique plasmid (*i.e.*, one unique insert) per transfected amoeba (Fig. S6).

To screen for growth phenotypes, growth rates were measured for a selected number of clonal lines. Slow Growth mutants 1 (SG1) and 2 (SG2) were isolated first and chosen for further characterization. These mutants had inserts corresponding to EHI_194310 and EHI_007010, which are annotated as a putative amino acid transporter and a hypothetical protein, respectively (Table 2). These mutants had a statistically significant growth defect (Fig. 5a). We have previously knocked down superoxide dismutase (EHI_159160) and determined that this results in a growth defect; thus, superoxide dismutase RNAi was used as a control. RT-PCR analysis showed that EHI_194310 and EHI_007010 were knocked down in the corresponding mutants (Fig. 5b).

To determine if knockdown mutant phenotypes were reproducible, Gibson cloning was used to generate independent knockdown plasmids that contained a fragment of either EHI_194310 or EHI_007010, which differed from the fragment in the library mutants. *E. histolytica* was stably transfected with each of these new plasmids to create the independent knockdown mutants, SG1i and SG2i. Growth of heterogeneous, stable transfectants was measured, and these mutants had statistically significant growth defects (Fig. 5c). RT-PCR analysis demonstrated that the corresponding target genes were knocked down (Fig. 5d). The library mutants and independently generated mutants each exhibited statistically significant growth defects (Fig. 5e). Thus, the phenotypes seen in library mutants were reproduced in independently generated mutants.

Localization and domain analysis of proteins targeted in slow growth mutants

To further characterize SG1 and SG2, protein localization was examined. SG1 is annotated as a putative amino acid transporter (Table 2), with predicted transmembrane domains, but no predicted signal peptide sequence. SG2 is annotated as a hypothetical protein (Table 2), with no annotated domains. SG2 also lacks predicted transmembrane domains, predicted lipid modification sites, and a predicted signal peptide sequence. Thus, the localization of neither protein could be definitively inferred from sequence analysis.

We found that SG1 was localized to the amoeba surface and was also detected intracellularly in the cytoplasm, and intracellularly with a punctate distribution (Fig. 6a – 6b, S8). Since these transfectants were heterogeneous, there was heterogeneity in the intensity of SG1 staining. Interestingly, amoebae overexpressing full-length SG1 consistently exhibited brighter DAPI staining (Fig. 6c) and/or more dividing cells with two nuclei,

compared to wild-type amoebae (Fig. 6a – 6b), suggesting that the growth rate was higher in these amoebae. Growth analysis showed that amoebae overexpressing full-length SG1 grew faster than vector control transfectants (Fig. 6d). To gain a deeper understanding of domains required for SG1 function, a C-terminal truncation mutant was overexpressed, and since it did not lead to increased growth, we concluded that this truncation interfered with protein function (Fig. 6d).

Unlike SG1, SG2 was not detectable on the amoeba surface. Instead, SG2 exhibited staining throughout the amoeba cytoplasm (Fig. 7a, S8). Since these transfectants were heterogeneous, there was heterogeneity in the intensity of SG2 staining. Overexpression of full-length SG2 was not associated with increased growth, and no difference was detected in the intensity of DAPI staining between SG2 overexpressors and wild-type cells (Fig. 7b). Unlike the rabbit antibody used to localize SG1 (Fig. 6a – 6b), the mouse antibody used to localize SG2 was associated with some background nuclear staining in wild-type cells (Fig. 7b, 7c, S8). By contrast, nuclear staining was not pronounced in SG2 overexpressors (Fig. 7b, 7c, S8).

Bioinformatic analysis of slow growing mutants

From the pilot RNAi library transfection, ~64 additional clonal lines were obtained and 10 additional clonal lines with statistically significant growth defects were identified (Fig. S7; Table 2). The insert present in each clonal line was identified by Sanger sequencing, and the results were again consistent with one unique plasmid per transfected amoeba. Inserts ranged in size from 322 to 555 bp. In previous studies that used pTrigger for gene silencing, the gene of interest for knockdown was in the forward orientation and in frame

with the trigger [25, 27-29, 40, 41]. In the slow growth mutants, inserts were in the forward or reverse orientation, and in and out of frame (Table 2). Inserts that were in the reverse orientation and out of frame, like SG1, nonetheless led to measurable knockdown (Fig. 5b). Both the directionality of the gene of interest, and the frame, are therefore dispensable for knockdown.

Nine of the twelve slow growth mutants contained an insert that mapped to a gene (Table 2). The three mutants with inserts that did not clearly map to an annotated gene (SG3, SG9 and SG12) did map to potentially unannotated ORFs, and also partially mapped (*i.e.*, contained stretches of homology) to annotated genes. BLAST was used to search for homologs of the ORFs that mapped to SG3, SG9, and SG12, and homologs were found in *E. dispar* for each ORF (Expect values of $4e^{-31}$, $1e^{-10}$, $1e^{-9}$, respectively), suggesting that these ORFs are genes that were missed in the annotation of the *E. histolytica* genome. The *E. histolytica* genome contains a very large number of gene families [8, 9], evidencing a high level of functional redundancy. One mutant, SG5, contained an insert that mapped to more than one gene (Table 2). Due to the level of identity between the multiple hits, multiple related genes may be knocked down in this mutant.

Several mutants contained inserts that mapped to genes with annotated functions consistent with roles necessary for cellular growth, such as an amino acid transporter, a major facilitator transporter, and a splicing factor (Table 2). Three mutants contained inserts with predicted roles in metabolic pathways, based on data from KEGG Metabolic Pathways (<https://www.kegg.jp>), the MetaCyc Metabolic Pathway Database [42], and Chemical Entities of Biological Interest (ChEBI) database [43] (Table 2). Several mutants

307 contained inserts that mapped to genes annotated as hypothetical, or that lacked
308 annotated domains (Table 2). Thus, in addition to validating the RNAi library approach, the
309 12 slow growth mutants that were uncovered shed light on genes that are required for *E.*
310 *histolytica* growth and emphasize how forward genetics can be used to assign functional
311 information to hypothetical proteins.

Discussion

We constructed and validated the first genome-wide *E. histolytica* RNAi knockdown mutant library. We performed a screen for slow growth mutants and identified 12 new mutants, providing a proof-of-concept that demonstrates the library can be used to identify mutant phenotypes. Independent knockdown mutants phenocopied the growth defects seen in the library mutants, showing that library mutant phenotypes are reproducible. Thus, our studies both identify genes that are critical for growth, and establish RNAi-based forward genetics in *E. histolytica* for the first time. The library represents a valuable new tool for *E. histolytica*, that can now be applied towards the study of many processes.

Slow growth mutants were identified among clonal knockdown mutant lines. 12 mutants were identified among ~80 total clonal lines. Among the identified genes targeted in these mutants, many genes had annotated functions consistent with roles in cellular growth, and/or had predicted roles in metabolic pathways, based on available metabolic pathway databases (<https://www.kegg.jp/>) [42, 43]. No genes were identified for which a role in cellular growth would be implausible. Several of the identified genes were annotated as hypothetical, or lacked annotated domains. All of the gene hits in our screen had previous evidence of gene expression in RNAseq analyses [44, 45]. Thus, the slow growth phenotype begins to provide functional information to genes for which existing annotation does not inform understanding of protein function. All of the annotated gene hits in our screen had homologues in the related human-infectious *Entamoeba* species *E. dispar*, *E. nuttali* and *E. moshkovskii*. Thus, this type of screen may be informative in identifying potential drug targets that are conserved among human-infectious *Entamoeba* species.

The *E. histolytica* genome contains numerous gene families [8, 9]. An advantage of RNAi vs. alternative approaches (*e.g.*, gene knockouts) is the potential to simultaneously interfere with multiple gene family members. RNAi is similarly advantageous for genomes that are polyploid, which is also relevant to the tetraploid [7] *E. histolytica* genome. We identified one mutant that contained an insert that mapped to more than one gene. With the high levels of sequence identity, it is likely that multiple genes are knocked down in this mutant. We were able to identify a slow growth phenotype in this mutant, which suggests that the RNAi library may be effective in identifying mutant phenotypes even in the context of high levels of functional redundancy.

We have used pTrigger to knockdown many genes in our laboratory, and, in general, have been able to recover knockdown mutants for essentially every targeted gene. Compared to clonal lines, heterogeneous transfectants have typically had more variable levels of knockdown, and sometimes appear to have lower levels of knockdown [46]. We obtain clonal lines by limiting dilution, but another effective available method is cloning by isolating *E. histolytica* colonies on soft agar plates [47]. Among clonal lines obtained from heterogeneous transfectants, we have seen wide variation, including clones with high levels of knockdown and clones that lack knockdown. The SG1 and SG2 clonal lines initially obtained from the library appeared to have an equal or higher level of knockdown than the heterogeneous independent SG1i and SG2i mutants that targeted the same gene. The heterogeneous independent knockdown mutant SG1i had a less severe growth phenotype than the clonal library mutant SG1, which may be due to variation in knockdown in the heterogeneous population. Loss of gene silencing (and loss of a growth phenotype) over

time was noted in the heterogeneous SG2i mutants (data not shown), consistent with the selective disadvantage of the growth phenotype. Related to this point, when a selection is applied to a library mutant population, it will be important to compare selected and non-selected controls, in order to differentiate mutants that are lost due to a growth disadvantage vs. mutants that are lost due to selection.

The library was designed to facilitate Illumina deep sequencing analysis in order to quantitatively identify mutants that are enriched or lost after selection. We constructed pilot and final versions of the library. Multiple lines of evidence supported that there was no bias in library construction, including nucleotide and dinucleotide frequencies, and size comparisons between the gDNA fragments and fragments in the final plasmids. Libraries were prepared in batches that were cloned on different days. Similar read counts per fragment were obtained from batches, again supporting that there was no bias in cloning or sequencing analysis. The majority of the genome (97.24%) was covered in the final plasmid library, and the majority of genes were represented (8307 out of 8333 annotated genes). 26 annotated genes are not represented. Of these, 22 genes were not seen in any sample, including gDNA, suggesting that they represent errors in annotation. Consistent with this, there was no published evidence for gene expression for the majority of these genes. The 4 remaining genes that were not seen in the final library had some of the lowest sequencing coverage in the fragmented gDNA sample, suggesting that they were missed due to lack of abundance in the fragmented gDNA that was used for library construction. Thus, with 8307 out of 8311 correctly annotated genes represented, and 97.24% of the genome, we concluded that the library represented full genome coverage.

A future variation on this approach would be to make a library using fragmented cDNA instead of gDNA. We reasoned that since ~50% of the genome is coding, gDNA is a reasonable approach, since ~50% of the plasmids in the library would lead to gene silencing. A limitation of a gDNA library is that some sequences such as rRNA and tRNA, which are abundant in the genome, are represented in the library, and are not useful for identification of mutant phenotypes. A cDNA library would remove these sequences, but would carry other limitations. The most highly expressed genes would be overrepresented in a cDNA library, and genes that are not expressed in the conditions in which cDNA was obtained would not be represented in the library. The lower abundance of material for fragmentation and cloning is also a consideration. mRNA is a very small proportion of total RNA, and in our initial attempts to prepare cDNA for library construction, insufficient material was recovered. With more initial total RNA, a cDNA library could be constructed in the future, and would be complementary to the gDNA library that was constructed here.

We asked whether the frame or the directionality of the insert was critical for knockdown using the trigger plasmid. In previous studies, the gene of interest for knockdown was in the forward orientation and in frame with the trigger [25, 27-29, 40, 41]; thus, the frame and orientation requirements had not been tested experimentally. Among the slow growth mutants that we identified, inserts were in the forward or reverse orientation, and in and out of frame. Note that the adaptor sequence that was inserted between the trigger and the insert does not change the frame. Inserts that were in the reverse orientation and out of frame still led to knockdown. Both the directionality of the gene of interest, and the frame, are therefore dispensable for knockdown. Since the RNAi

pathway in *E. histolytica* is unusual and mechanistic details are still coming into focus, our results add to understanding of this pathway. The lack of orientation and frame requirements for knockdown is useful, since gDNA fragments are random and thus are ligated into the library plasmid in either orientation and in any frame. Previous studies had defined that a gene fragment ≥ 500 bp is sufficient for knockdown [25, 40]. We found that fragments as small as 322 bp were sufficient to result in slow growth phenotypes, suggesting that efficient knockdown is possible with smaller fragments.

E. histolytica is dramatically understudied relative to other parasites, even though it heavily impacts human health, causing significant morbidity and mortality. The RNAi library that we developed dramatically improves the tractability of *E. histolytica*. In other parasites, RNAi screens have uncovered genes relevant to molecular and cellular biology, virulence and therapeutics. We look forward to the new information about *E. histolytica* that can be gleaned by applying RNAi screens in the future. Since the design of this RNAi library allows for quantitative identification of mutants that are enriched or depleted after selection, we expect that this library can be used to identify genes involved in a wide variety of processes, including essential genes that are relevant to the development of new therapies.

Materials and Methods

Cell culture

E. histolytica HM1:IMSS (ATCC 30459) trophozoites were cultured in TYI-S-33 media, supplemented with 15% heat inactivated Adult Bovine Serum (Gemini Bio Products), 80 units/ml penicillin and streptomycin (Gibco), and 2.3% Diamond Vitamin solution 80 Tween 40x (Sigma Aldrich), at 35°C. Amoebae were harvested when flasks were approximately 80% confluent.

gDNA Extraction

E. histolytica gDNA was harvested using the Quick-DNA miniprep kit (Zymo), cetyl trimethylammonium bromide (CTAB) extraction, or the Wizard gDNA extraction kit (Promega). The Quick-DNA miniprep kit (Zymo) was used according to manufacturer's instructions for cell suspension samples. For CTAB extraction, cells were washed and then lysed at 55°C for 1 hour in a solution of 0.1 M EDTA with 0.25% SDS and 0.1 mg/ml proteinase K. NaCl was added to a final concentration of 0.7 M, pre-warmed CTAB was added to a final concentration of 1%, and samples were incubated for 20 minutes at 65°C. An equal volume of chloroform was added, and samples were centrifuged at 20,600 x *g* for 10 minutes. Supernatants were transferred into fresh tubes, an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added, and samples were centrifuged at 20,600 x *g* for 10 minutes. Supernatants were transferred into fresh tubes, DNA was precipitated with 2.5 volumes of 100% ethanol at room temperature for 5 minutes, and samples were centrifuged at 20,600 x *g* for 10 minutes. DNA pellets were washed in 70% ethanol. DNA was left to dry at room temperature and dissolved in water. For DNA harvested using the Quick-DNA miniprep kit or CTAB extraction, RNaseIF (NEB) was used to

remove RNA contamination, according to manufacturer's instructions. The Wizard Genomic DNA Purification kit (Promega) was used according to the manufacturer's instructions for the tissue culture cells protocol. Because DNA harvested using the Wizard Genomic DNA Purification kit was of higher quality, gDNA for plasmid library construction was prepared using this kit.

Plasmids and cloning

The trigger plasmid [25] contains 132 base pairs of the trigger gene (EHI_048600) in the pKT3M expression plasmid backbone [48]. Q5 Site Directed Mutagenesis (NEB) was used to insert a SmaI restriction enzyme site after the trigger for cloning purposes, to create "pTrigger". To create knockdown plasmids to target individual genes, pTrigger was linearized using SmaI (NEB) and dephosphorylated using rSAP (NEB). A fragment of the gene of interest was amplified from gDNA using PCR primers that contained homology to pTrigger, and the PCR product was then cloned into the backbone using the Gibson Assembly Ultra kit (Synthetic Genomics Inc.), following the manufacturer's instructions. See Table S4 for the sequences of primers that were used during plasmid construction.

To test if the Illumina adaptor sequences interfere with knockdown, pTrigger plasmids were created with and without adaptors. First, a pTrigger plasmid targeting a BAR/SH3 domain-containing protein was created by inserting 812 bp of EHI_091500 (147 – 958). This plasmid was further modified using Q5 Site Directed Mutagenesis (NEB) to add the custom adaptors ACACTCTTCCCTACACGACGCTCTCCGATCT and GATCGGAAGAGCACACGTCTGAACTCCAGTCAC, which are compatible with Illumina TruSeq sequencing primers, upstream and downstream of the insert, respectively. After determining that the presence of the Illumina adaptors did not

interfere with knockdown, this construct was modified to remove the BAR/SH3 domain-containing protein and replace it with a SmaI restriction site for further cloning purposes, to create pTriggerAdaptor. pTriggerAdaptor was used as the backbone for plasmid library generation.

Superoxide dismutase knockdown mutants were generated by inserting 597 bp of EHI_159160 (1 – 597) into pTrigger. Independent knockdown mutants (SG1i) of SG1 were generated by inserting 525 bp of EHI_194310 (32 – 556) into pTrigger. Independent knockdown mutants (SG2i) of SG2 were generated by inserting 487 bp of EHI_007010 (59 – 545) into pTrigger.

To create the N terminal FLAG-tag constructs, Q5 Site Directed Mutagenesis (NEB) was used to insert a 3X FLAG epitope tag sequence preceding an XhoI restriction site in the pEhEx expression plasmid backbone [48], to create pEhEx-FLAG. For localization of SG1 (EHI_194310) and SG2 (EHI_007010), each individual full-length gene was cloned into pEhEx-FLAG, to create pEhEx-FLAG-SG1 and pEhEx-FLAG-SG2, respectively. For expression of truncated SG1, nt 1010-1527 were omitted, and the resulting truncated gene was cloned into pEhEx-FLAG, with a stop codon added at the 3' end of the truncated sequence.

Plasmid library construction

E. histolytica gDNA was harvested using the Wizard Genomic DNA Purification kit (Promega), following the manufacturer's instructions for the tissue culture cells protocol. RNase treatment is included in this protocol. Quality and size of gDNA was verified by Qubit and gel electrophoresis. gDNA was further purified and concentrated using TailorMag Purification beads (SeqMatic), and then sheared using a Covaris M220 sonicator. For size

selection, sheared gDNA was loaded into three lanes on a 6% TBE gel. The gel was stained using SYBR Safe DNA Gel Stain (Invitrogen), and three bands, covering from ~400 – ~600 bp (for the pilot library) and ~500 – ~900 bp (for the final library) were extracted from the gel using the TailorCut Gel Cutter and Gel Breaker system (SeqMatic). gDNA was purified using TailorMag Purification beads. The sizing and concentration of the purified material was determined by TapeStation (Agilent). Purified gDNA corresponding to the second and third gel slices from each lane was combined. gDNA was further purified and concentrated using TailorMag Purification beads, and then processed using a TruSeq XT library prep kit (Illumina). All steps followed the manufacturer's protocol except: 1. Ligation time was increased to 180 minutes, 2. Custom adaptors were used instead of Illumina TruSeq adaptors. The adaptors that were ligated had the following sequences: Adaptor 1: ACACTCTTCCCTACACGACGCTCTCCGATCCCC*T and Adaptor 2: /5'Phos/GGGGATCGGGAGAGCACACGTCTGAACTCTAGTCAC. After adaptor ligation, the gDNA fragments were amplified using 5 rounds of PCR with KAPA HiFi 2X master mix (KAPA Biosystems). See Table S4 for primer sequences. After PCR, fragmented gDNA was purified and concentrated using TailorMag Purification beads.

pTriggerAdaptor was linearized using SmaI (NEB) and dephosphorylated using rSAP (NEB). Linearization was verified using gel electrophoresis. 25 ng of fragmented gDNA with ligated adaptors was combined with 25 ng of linearized pTriggerAdaptor. The Gibson Assembly Ultra kit (Synthetic Genomics Inc.) was used according to the manufacturer's instructions. High Efficiency 5-alpha Competent *E. coli* (NEB) were transformed with 3 µl of the Gibson mix and plated on four LB plates containing ampicillin (Sigma). We determined that the Gibson cloning efficiency with pTriggerAdaptor was ~1/250, which was used to calculate the amount of insert

needed to generate a library at a given target level of coverage. With an average insert size of ~550 bp, a minimum of ~36,354 plasmids would be needed to fully cover the genome at 1X coverage. For the pilot library, one *E. coli* transformation reaction was performed and 4 plates of bacteria were harvested into 200 ml of LB liquid broth containing ampicillin, and incubated at 37°C for 12-18 hours, shaking. For the final library, Gibson cloning, *E. coli* transformation, and plasmid preparations were performed over four separate days to create four batches of final library plasmids. The final plasmid library represents the combined total of the four batches. For the final library, 25 *E. coli* transformation reactions were performed and 100 plates of bacteria were harvested into LB liquid broth containing ampicillin, at a concentration of ~1,000 colonies per 200 ml. Plasmids were harvested using the GenElute HP plasmid maxiprep kit (Sigma), using 200 ml of culture per plasmid purification column, and ethanol precipitated according to the manufacturer's instructions.

Illumina sequencing of gDNA fragments and plasmid samples

Fragmented gDNA (with ligated custom adaptors; see 'plasmid library construction'), or plasmid inserts were amplified with KAPA PCR (Kapa Biosystems) using full length TruSeq Illumina primers, as follows: Primer 1: GATCGGAAGAGCACACGTCTGAACTCCAGTCAC[i7]ATCTCGTATGCCGTCTTCTGCTTG and Primer 2: AATGATACGGCGACCACCGAGATCTACAC[i5]ACACTCTTTCCCTACACGACGCTCTTCCGATCT. Three technical replicates were sequenced for each sample. Samples were sequenced on an Illumina MiSeq at either the DNA Technologies and Expression Analysis Core (University of California, Davis), or on an Illumina MiSeq at SeqMatic, LLC. Illumina sequencing data analysis was performed at the Bioinformatics Core (University of California, Davis).

Illumina sequencing analysis

Illumina sequencing data was demultiplexed using barcode sequences added during library preparation with Illumina demultiplexing software. All reads were sequenced as PE 151bp runs. The resulting paired reads were then cleaned using HTStream (<https://github.com/ibest/HTStream>) to 1) remove reads containing PhiX Control Library sequences, 2) trim Illumina sequencing adaptors, and 3) discard primer dimers and other reads where adaptor trimming was unsuccessful.

Cleaned reads were mapped against the *E. histolytica* release 46 genome assembly (downloaded from https://amoebadb.org/common/downloads/release-46/EhistolyticaHM1IMSS/fasta/data/AmoebaDB-46_EhistolyticaHM1IMSS_Genome.fasta) using bwa mem v2.0pre1 [49]. Output from bwa was passed to samtools v1.10 [50] for sorting and indexing, and also to extract reads from for visualization of specific loci. Results from mapping and subsequent analysis were visualized and reviewed in Geneious Prime 2020.0.3 (<https://www.geneious.com>). Identifying unique fragments and counting their frequency was done using a custom Python script. Briefly, the script iterates over read-sorted BAM records. Read pairs that were mapped to the same contig with proper orientation, a minimum of 146 matched bases, and no more than four bases soft clipped from the 5' end of either read pair were used to identify fragments. Read mapping orientation was used to infer fragment orientation. A counter for each unique fragment was incremented for additional reads supporting the fragment. Reads that were mapped in proper orientation but that did not meet other criteria were compared against the fragment intervals with an incremented count

assigned to the highest scoring overlap. As a last step, the script generates summary statistics, an interval table with counts for all samples, and SAF and gff annotation files for each sample.

Output from the Python script was then loaded into R v3.6.1 [51] for further analysis and to generate figures. Briefly, `data.table` [52] was used to load the full set of intervals, order them by genomic position, and to compute summaries by sample group. `Tidyr` [53] was used for reformatting data, and most plots were generated with `ggplot2` [54]. The `vegan` package [55] was used for calculating saturation curve values. The `GenomicRanges` package [56] was used in combination with gene annotation (downloaded from https://amoebadb.org/common/downloads/release-46/EhistolyticaHM1IMSS/gff/data/AmoebaDB-46_EhistolyticaHM1IMSS.gff) to determine and count fragments targeting genes, all reported counts used a minimum overlap of 27bp. Genome coverage plots were generated with `karyoploteR` [57] and heatmaps were plotted using `pheatmap` [58]. Scripts and more details about the analysis are available at the GitHub repository associated with this publication: <https://github.com/samhunter/Bettadapur-et-al-Entamoeba-histolytica-RNAi-library>.

All sequencing data from this project have been deposited in the Sequence Read Archive (SRA) database (<https://www.ncbi.nlm.nih.gov/sra>), under project number SUB7459667.

Transfection and clonal lines

Library plasmids were transfected into amoebae using Attractene transfection reagent (Qiagen) [59, 60]. 50 ml M199 (Gibco medium M199 with Earle's salts, L-glutamine, and 2.2 g/liter sodium bicarbonate, without phenol red), was supplemented with 0.045 g L-Cysteine, 0.3 g HEPES, 0.005 g ascorbic acid (all from Sigma) and the pH was adjusted to 6.8. To 42.5 ml of

this medium, 7.5 ml of heat inactivated Adult Bovine Serum (Gemini bio-products) was added to make transfection medium. Amoebae were resuspended in transfection medium at a concentration of 2.5×10^5 cells/ml, and then 1.8 ml of amoebae, 10 μ g plasmid DNA (in 200 μ l of transfection medium), and 37.5 μ l Attractene reagent (Qiagen) were combined into a 2.0 ml screw-cap cryotube. Cryotubes were incubated horizontally at 35°C for 3 hours. Two cryotubes per transfection were then added to a T25 flask containing 66 ml of fresh TYI media. 24 hours later, 6 μ g/ml geneticin (Invitrogen) was added. Stable transfectants were selected and maintained with geneticin at 6 μ g/ml.

The efficiency of stable transfection was determined by performing limiting dilution. Three independent experiments were performed. Amoebae were transfected using the process described above, except that 24 hours after transfection, amoebae were harvested and resuspended in TYI at a concentration of 2×10^6 cells/ml. Amoebae were then serially diluted into 96-well plates, in the presence or absence of 6 μ g/ml geneticin. Plates were incubated in GasPak EZ pouch (BD Biosciences) and growth was monitored daily. The plates without Geneticin were used to calculate the plating efficiency. In the plates without geneticin, growth was seen in wells corresponding to approximately 2.5 cells on average. In the plates containing geneticin, growth was seen in wells containing 781 to 3125 amoebae. Taken together, the corrected stable transfection efficiency was $\sim 1/1000$ amoebae.

For generation of clonal mutant lines for phenotypic characterization, limiting dilution was performed in 96-well plates in a GasPak EZ pouch (BD Biosciences). For identification of mutants with growth defects, clonal lines that visually appeared to have slow growth when examined using microscopy were selected for further analysis. RNA was extracted using the

Direct-zol RNA kit (Zymo). gDNA (which contains exogenous plasmids) was extracted using the Quick-DNA miniprep kit (Zymo). Sanger sequencing was used to identify the library insert associated with each clonal line. Sequencing was carried out by Genewiz. To identify the gene targeted for knockdown in each clonal line, the insert sequence was used to search the reference genome. Genes with at least 50nt of continuous sequence identity with the insert were considered hits. See Table S4 for sequencing primer information.

Growth analysis

For growth analysis of RNAi knockdown mutants, clonal stable transfectants (SG1 – SG12) or heterogeneous stable transfectants (SG1i and SG2i) were resuspended to 8×10^3 cells/ml and 1 ml of cells was added to three tubes containing 13 ml fresh TYI with geneticin. Cells were incubated at 35°C. At days 2, 4, and 6, one tube of cells was harvested per day and counted using a TC20 Automatic cell counter (BioRad). Vector control transfected amoebae were used as a negative control, and superoxide dismutase heterogeneous knockdown mutants were used as a positive control for slow growth. Two technical replicates were performed per experiment and three independent growth curve experiments were performed for each mutant.

For growth analysis of cells overexpressing full-length or truncated SG proteins, geneticin concentration was doubled daily until it reached 48 µg/ml, in order to increase plasmid copy number and lead to protein overexpression. Geneticin concentration was also increased in the same manner in vector control transfectants. Heterogeneous stable transfectants were resuspended to 5×10^4 cells/ml and 1 ml of cells was added to five tubes containing 13 ml fresh TYI with 48 µg/ml geneticin. Cells were incubated at 35°C. At days 1, 2, 3,

4 and 5, one tube of cells was harvested per day and counted using a TC20 Automatic cell counter (BioRad). Vector control transfected amoebae were used as a negative control. Four technical replicates were performed per experiment and three independent growth curve experiments were performed for each cell line. Growth curves were also performed at 24 µg/ml geneticin, which led to the same growth phenotypes seen at higher concentrations of geneticin.

RT-PCR

RT-PCR was used to assess knockdown in transfectants. RNA was extracted using the Direct-zol RNA kit (Zymo). DNaseI (Turbo) treatment and SuperScript Reverse Transcription II (Invitrogen) was performed as per manufacturer instructions to obtain cDNA. RT-PCR was performed on cDNA harvested from transfectants containing the following constructs: BAR/SH3 domain-containing protein with and without Illumina adaptors, Superoxide Dismutase; SG1/SG1 independent knock down; and SG2/SG2 independent knockdown. GAPDH (EHI_187020) RT-PCR was used as a positive control. See Table S4 for RT-PCR primer sequences.

Immunofluorescence assays

For immunofluorescence studies, geneticin concentration was doubled daily until it reached 24 µg/ml, in order to increase plasmid copy number and lead to protein overexpression. Amoebae were washed in M199s and fixed with 4% paraformaldehyde in PBS for 30 minutes at room temperature. Samples were permeabilized with 0.2% Triton X-100, or were not permeabilized. For permeabilized samples, for SG1, all subsequent blocking, antibody incubation and wash steps included 0.1% Triton X-100. For permeabilized samples, for SG2, all subsequent blocking, antibody incubation and wash steps included 0.1% Tween 20. For non-permeabilized samples, all subsequent blocking, antibody incubation and wash steps included

0.1% Tween 20. Samples were blocked with goat serum (Jackson ImmunoResearch Laboratories, Inc.) and bovine serum albumin (Gemini). Antibody labeling was carried out in solution. For SG1, a rabbit anti-FLAG primary antibody (Abcam Rabbit Anti-DDDDK tag, binds to FLAG tag sequence, antibody ab1162) was used, followed by an alpaca anti-rabbit Alexa 647 secondary antibody (Jackson ImmunoResearch Laboratories, Inc.). For SG2, a mouse anti-FLAG primary (Sigma Mouse Anti-FLAG M2 monoclonal antibody) was used, followed by an alpaca anti-mouse Cy5 antibody (Jackson ImmunoResearch Laboratories). Samples were stained with DAPI at 40 µg/ml. Data were collected using an ImageStreamX Mark II flow cytometer, equipped with a 40X objective. 10,000 events were collected for each sample and data were analyzed using Amnis IDEAS software (Fig. S8).

Statistical analysis

GraphPad Prism was used for student's unpaired *t* test statistical analysis and normalization (baseline removal). Mean values and standard deviations are shown in the figures, with *t* test values reported as follows: ns = $p > 0.05$, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$.

Acknowledgements

We thank Hannah Miller, Rene Suleiman, Scott Dawson and Su-Ju Lin for helpful discussions. We thank Lutz Froenicke for helpful advice on designing the library to enable Illumina sequencing. DNA sequencing was carried out by the DNA Technologies and Expression Analysis Cores at the UC Davis Genome Center, supported by NIH Shared Instrumentation Grant 1S10OD010786-01. A.B. was supported by a fellowship from the UC Davis Training Program in Biomolecular Technology. M.C.R. was supported by the NIH T32 Comparative Medical Science Training Program, T32OD011147. This work was funded by NIH grants 1R01AI146914, 5R21AI154163 and a Pew Scholarship awarded to K.S.R.

659 **Competing Interests**

660 The authors declare that they have no competing interests.

References

1. WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January, 1997. Epidemiol Bull. 1997;18(1):13-4. Epub 1997/03/01. PubMed PMID: 9197085.
2. Gilchrist CA, Petri SE, Schneider BN, Reichman DJ, Jiang N, Begum S, et al. Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite *Entamoeba histolytica*. J Infect Dis. 2016;213(10):1579-85. Epub 2015/12/30. doi: 10.1093/infdis/jiv772. PubMed PMID: 26712950; PubMed Central PMCID: PMC4837909.
3. Mondal D, Petri WA, Jr., Sack RB, Kirkpatrick BD, Haque R. *Entamoeba histolytica*-associated diarrheal illness is negatively associated with the growth of preschool children: evidence from a prospective study. Trans R Soc Trop Med Hyg. 2006;100(11):1032-8. Epub 2006/05/30. doi: S0035-9203(06)00066-6 [pii] 10.1016/j.trstmh.2005.12.012 [doi]. PubMed PMID: 16730764.
4. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382(9888):209-22. doi: 10.1016/S0140-6736(13)60844-2. PubMed PMID: 23680352.
5. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. Epub 2014/12/23. doi: 10.1016/S0140-6736(14)61682-2. PubMed PMID: 25530442; PubMed Central PMCID: PMC4340604.
6. Gonzales MLM, Dans LF, Sio-Aguilar J. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2019;1:CD006085. Epub 2019/01/10. doi: 10.1002/14651858.CD006085.pub3. PubMed PMID: 30624763; PubMed Central PMCID: PMC6326239.
7. Willhoeft U, Tannich E. The electrophoretic karyotype of *Entamoeba histolytica*. Mol Biochem Parasitol. 1999;99(1):41-53. Epub 1999/04/24. doi: 10.1016/s0166-6851(98)00178-9. PubMed PMID: 10215023.
8. Lorenzi HA, Puiu D, Miller JR, Brinkac LM, Amedeo P, Hall N, et al. New assembly, reannotation and analysis of the *Entamoeba histolytica* genome reveal new genomic features and protein content information. PLoS Negl Trop Dis. 2010;4(6):e716. Epub 2010/06/19. doi: 10.1371/journal.pntd.0000716. PubMed PMID: 20559563; PubMed Central PMCID: PMC2886108.
9. Wilson IW, Weedall GD, Lorenzi H, Howcroft T, Hon CC, Deloger M, et al. Genetic Diversity and Gene Family Expansions in Members of the Genus *Entamoeba*. Genome Biol Evol. 2019;11(3):688-705. Epub 2019/01/23. doi: 10.1093/gbe/evz009. PubMed PMID: 30668670; PubMed Central PMCID: PMC6414313.
10. Loftus B, Anderson I, Davies R, Alsmark UC, Samuelson J, Amedeo P, et al. The genome of the protist parasite *Entamoeba histolytica*. Nature. 2005;433(7028):865-8. Epub 2005/02/25. doi: nature03291 [pii] 10.1038/nature03291 [doi]. PubMed PMID: 15729342.

11. King AV, Welter BH, Koushik AB, Gordon LN, Temesvari LA. A genome-wide over-expression screen identifies genes involved in phagocytosis in the human protozoan parasite, *Entamoeba histolytica*. *PLoS One*. 2012;7(8):e43025. doi: 10.1371/journal.pone.0043025. PubMed PMID: 22905196; PubMed Central PMCID: PMC3419234.
12. Koushik AB, Welter BH, Rock ML, Temesvari LA. A genomewide overexpression screen identifies genes involved in the phosphatidylinositol 3-kinase pathway in the human protozoan parasite *Entamoeba histolytica*. *Eukaryot Cell*. 2014;13(3):401-11. doi: 10.1128/EC.00329-13. PubMed PMID: 24442890; PubMed Central PMCID: PMC3957588.
13. Bracha R, Nuchamowitz Y, Leippe M, Mirelman D. Antisense inhibition of amoebapore expression in *Entamoeba histolytica* causes a decrease in amoebic virulence. *Mol Microbiol*. 1999;34(3):463-72. Epub 1999/11/17. doi: mmi1607 [pii]. PubMed PMID: 10564488.
14. Bracha R, Nuchamowitz Y, Anbar M, Mirelman D. Transcriptional silencing of multiple genes in trophozoites of *Entamoeba histolytica*. *PLoS Pathog*. 2006;2(5):e48. Epub 2006/05/31. doi: 10.1371/journal.ppat.0020048 [doi]. PubMed PMID: 16733544.
15. Bracha R, Nuchamowitz Y, Mirelman D. Transcriptional silencing of an amoebapore gene in *Entamoeba histolytica*: molecular analysis and effect on pathogenicity. *Eukaryot Cell*. 2003;2(2):295-305. Epub 2003/04/10. PubMed PMID: 12684379; PubMed Central PMCID: PMC154849.
16. Stock RP, Olvera A, Sanchez R, Saralegui A, Scarfi S, Sanchez-Lopez R, et al. Inhibition of gene expression in *Entamoeba histolytica* with antisense peptide nucleic acid oligomers. *Nat Biotechnol*. 2001;19(3):231-4. Epub 2001/03/07. doi: 10.1038/85671. PubMed PMID: 11231555.
17. Kaur G, Lohia A. Inhibition of gene expression with double strand RNA interference in *Entamoeba histolytica*. *Biochemical and biophysical research communications*. 2004;320(4):1118-22. Epub 2004/07/14. doi: 10.1016/j.bbrc.2004.06.064. PubMed PMID: 15249205.
18. Solis CF, Santi-Rocca J, Perdomo D, Weber C, Guillen N. Use of bacterially expressed dsRNA to downregulate *Entamoeba histolytica* gene expression. *PLoS One*. 2009;4(12):e8424. Epub 2009/12/29. doi: 10.1371/journal.pone.0008424. PubMed PMID: 20037645; PubMed Central PMCID: PMC2793006.
19. Linford AS, Moreno H, Good KR, Zhang H, Singh U, Petri WA, Jr. Short hairpin RNA-mediated knockdown of protein expression in *Entamoeba histolytica*. *BMC Microbiol*. 2009;9(1):38. Epub 2009/02/19. doi: 1471-2180-9-38 [pii] 10.1186/1471-2180-9-38 [doi]. PubMed PMID: 19222852.
20. Zhang H, Ehrenkaufer GM, Pompey JM, Hackney JA, Singh U. Small RNAs with 5'-polyphosphate termini associate with a Piwi-related protein and regulate gene expression in the single-celled eukaryote *Entamoeba histolytica*. *PLoS Pathog*. 2008;4(11):e1000219. Epub 2008/12/02. doi: 10.1371/journal.ppat.1000219. PubMed PMID: 19043551; PubMed Central PMCID: PMC2582682.
21. Sijen T, Steiner FA, Thijssen KL, Plasterk RH. Secondary siRNAs result from unprimed RNA synthesis and form a distinct class. *Science*. 2007;315(5809):244-7. Epub 2006/12/13. doi: 10.1126/science.1136699. PubMed PMID: 17158288.
22. Zhang H, Alramini H, Tran V, Singh U. Nucleus-localized antisense small RNAs with 5'-polyphosphate termini regulate long term transcriptional gene silencing in *Entamoeba*

- histolytica G3 strain. J Biol Chem. 2011;286(52):44467-79. Epub 2011/11/04. doi: M111.278184 [pii]
- 10.1074/jbc.M111.278184. PubMed PMID: 22049083; PubMed Central PMCID: PMC3247957.
23. Pompey JM, Foda B, Singh U. A Single RNaseIII Domain Protein from *Entamoeba histolytica* Has dsRNA Cleavage Activity and Can Help Mediate RNAi Gene Silencing in a Heterologous System. PLoS One. 2015;10(7):e0133740. doi: 10.1371/journal.pone.0133740. PubMed PMID: 26230096; PubMed Central PMCID: PMC4521922.
24. Zhang H, Tran V, Manna D, Ehrenkaufer G, Singh U. Functional Characterization of *Entamoeba histolytica* Argonaute Proteins Reveals a Repetitive DR-Rich Motif Region That Controls Nuclear Localization. mSphere. 2019;4(5). Epub 2019/10/18. doi: 10.1128/mSphere.00580-19. PubMed PMID: 31619501; PubMed Central PMCID: PMC6796981.
25. Morf L, Pearson RJ, Wang AS, Singh U. Robust gene silencing mediated by antisense small RNAs in the pathogenic protist *Entamoeba histolytica*. Nucleic Acids Res. 2013. doi: 10.1093/nar/gkt717. PubMed PMID: 23935116.
26. Foda BM, Singh U. Dimethylated H3K27 Is a Repressive Epigenetic Histone Mark in the Protist *Entamoeba histolytica* and Is Significantly Enriched in Genes Silenced via the RNAi Pathway. J Biol Chem. 2015;290(34):21114-30. doi: 10.1074/jbc.M115.647263. PubMed PMID: 26149683; PubMed Central PMCID: PMC4543668.
27. Pompey JM, Morf L, Singh U. RNAi pathway genes are resistant to small RNA mediated gene silencing in the protozoan parasite *Entamoeba histolytica*. PLoS One. 2014;9(9):e106477. Epub 2014/09/10. doi: 10.1371/journal.pone.0106477. PubMed PMID: 25198343; PubMed Central PMCID: PMC4157801.
28. Manna D, Lentz CS, Ehrenkaufer GM, Suresh S, Bhat A, Singh U. An NAD(+)-dependent novel transcription factor controls stage conversion in *Entamoeba*. eLife. 2018;7. Epub 2018/10/31. doi: 10.7554/eLife.37912. PubMed PMID: 30375973; PubMed Central PMCID: PMC6207428.
29. Suresh S, Ehrenkaufer G, Zhang H, Singh U. Development of RNA Interference Trigger-Mediated Gene Silencing in *Entamoeba invadens*. Infect Immun. 2016;84(4):964-75. Epub 2016/01/21. doi: 10.1128/IAI.01161-15. PubMed PMID: 26787723; PubMed Central PMCID: PMC4807475.
30. Morris JC, Wang Z, Drew ME, Englund PT. Glycolysis modulates trypanosome glycoprotein expression as revealed by an RNAi library. EMBO J. 2002;21(17):4429-38. Epub 2002/08/29. PubMed PMID: 12198145; PubMed Central PMCID: PMC125414.
31. Drew ME, Morris JC, Wang Z, Wells L, Sanchez M, Landfear SM, et al. The adenosine analog tubercidin inhibits glycolysis in *Trypanosoma brucei* as revealed by an RNA interference library. J Biol Chem. 2003;278(47):46596-600. Epub 2003/09/16. doi: 10.1074/jbc.M309320200. PubMed PMID: 12972414.
32. Stortz JA, Serafim TD, Alsford S, Wilkes J, Fernandez-Cortes F, Hamilton G, et al. Genome-wide and protein kinase-focused RNAi screens reveal conserved and novel damage response pathways in *Trypanosoma brucei*. PLoS Pathog. 2017;13(7):e1006477. Epub 2017/07/26. doi: 10.1371/journal.ppat.1006477. PubMed PMID: 28742144; PubMed Central PMCID: PMC5542689.

33. Glover L, Hutchinson S, Alsford S, Horn D. VEX1 controls the allelic exclusion required for antigenic variation in trypanosomes. *Proc Natl Acad Sci U S A*. 2016;113(26):7225-30. Epub 2016/05/27. doi: 10.1073/pnas.1600344113. PubMed PMID: 27226299; PubMed Central PMCID: PMC4932947.
34. Mony BM, MacGregor P, Ivens A, Rojas F, Cowton A, Young J, et al. Genome-wide dissection of the quorum sensing signalling pathway in *Trypanosoma brucei*. *Nature*. 2014;505(7485):681-5. Epub 2013/12/18. doi: 10.1038/nature12864. PubMed PMID: 24336212; PubMed Central PMCID: PMC43908871.
35. Rico E, Ivens A, Glover L, Horn D, Matthews KR. Genome-wide RNAi selection identifies a regulator of transmission stage-enriched gene families and cell-type differentiation in *Trypanosoma brucei*. *PLoS Pathog*. 2017;13(3):e1006279. Epub 2017/03/24. doi: 10.1371/journal.ppat.1006279. PubMed PMID: 28334017; PubMed Central PMCID: PMC5380359.
36. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. *Nature*. 2012;482(7384):232-6. Epub 2012/01/27. doi: 10.1038/nature10771. PubMed PMID: 22278056; PubMed Central PMCID: PMC3303116.
37. Collett CF, Kitson C, Baker N, Steele-Stallard HB, Santrot MV, Hutchinson S, et al. Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite *Trypanosoma brucei*. *Antimicrob Agents Chemother*. 2019;63(8). Epub 2019/06/05. doi: 10.1128/AAC.00795-19. PubMed PMID: 31160283; PubMed Central PMCID: PMC6658743.
38. Trenaman A, Glover L, Hutchinson S, Horn D. A post-transcriptional respiratome regulon in trypanosomes. *Nucleic Acids Res*. 2019;47(13):7063-77. Epub 2019/05/28. doi: 10.1093/nar/gkz455. PubMed PMID: 31127277; PubMed Central PMCID: PMC6648352.
39. Zhang N, Zoltner M, Leung KF, Scullion P, Hutchinson S, Del Pino RC, et al. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. *PLoS Pathog*. 2018;14(2):e1006850. Epub 2018/02/10. doi: 10.1371/journal.ppat.1006850. PubMed PMID: 29425238; PubMed Central PMCID: PMC5823473.
40. Khalil MI, Foda BM, Suresh S, Singh U. Technical advances in trigger-induced RNA interference gene silencing in the parasite *Entamoeba histolytica*. *Int J Parasitol*. 2016;46(3):205-12. doi: 10.1016/j.ijpara.2015.11.004. PubMed PMID: 26747561; PubMed Central PMCID: PMC4767557.
41. Rastew E, Morf L, Singh U. *Entamoeba histolytica* rhomboid protease 1 has a role in migration and motility as validated by two independent genetic approaches. *Exp Parasitol*. 2015. doi: 10.1016/j.exppara.2015.04.004. PubMed PMID: 25889553.
42. Caspi R, Billington R, Ferrer L, Foerster H, Fulcher CA, Keseler IM, et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. *Nucleic Acids Res*. 2016;44(D1):D471-80. Epub 2015/11/04. doi: 10.1093/nar/gkv1164. PubMed PMID: 26527732; PubMed Central PMCID: PMC4702838.
43. Hastings J, de Matos P, Dekker A, Ennis M, Harsha B, Kale N, et al. The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. *Nucleic Acids Res*. 2013;41(Database issue):D456-63. Epub 2012/11/28. doi: 10.1093/nar/gks1146. PubMed PMID: 23180789; PubMed Central PMCID: PMC3531142.

44. Shabardina V, Kischka T, Kmita H, Suzuki Y, Makalowski W. Environmental adaptation of *Acanthamoeba castellanii* and *Entamoeba histolytica* at genome level as seen by comparative genomic analysis. *Int J Biol Sci*. 2018;14(3):306-20. Epub 2018/03/22. doi: 10.7150/ijbs.23869. PubMed PMID: 29559848; PubMed Central PMCID: PMC5859476.
45. Hon CC, Weber C, Sismeiro O, Proux C, Koutero M, Deloger M, et al. Quantification of stochastic noise of splicing and polyadenylation in *Entamoeba histolytica*. *Nucleic Acids Res*. 2013;41(3):1936-52. Epub 2012/12/22. doi: 10.1093/nar/gks1271. PubMed PMID: 23258700; PubMed Central PMCID: PMC3561952.
46. Suleiman RL, Ralston KS. Growth and genetic manipulation of *Entamoeba histolytica*. *Curr Protoc*. 2021;Submitted.
47. Mueller DE, Petri WA, Jr. Clonal growth in Petri dishes of *Entamoeba histolytica*. *Trans R Soc Trop Med Hyg*. 1995;89(1):123. Epub 1995/01/01. doi: 10.1016/0035-9203(95)90684-3. PubMed PMID: 7747296.
48. Saito-Nakano Y, Yasuda T, Nakada-Tsukui K, Leippe M, Nozaki T. Rab5-associated vacuoles play a unique role in phagocytosis of the enteric protozoan parasite *Entamoeba histolytica*. *J Biol Chem*. 2004;279(47):49497-507. Epub 2004/09/07. doi: 10.1074/jbc.M403987200 [doi] M403987200 [pii]. PubMed PMID: 15347665.
49. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv e-prints*. 2013.
50. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9. Epub 2009/06/10. doi: 10.1093/bioinformatics/btp352. PubMed PMID: 19505943; PubMed Central PMCID: PMC2723002.
51. Team RC. R: A language and environment for statistical computing. R Foundation for statistical computing. 2019.
52. Dowle M, Srinivasan A. data.table: Extension of `data.frame`. R package version 1.12.8. 2019.
53. Wickham H, Henry L. tidy: Tidy Messy Data. R package version 1.0.2. 2020.
54. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag, New York. 2016.
55. Okansen J, Guillaume Blanchet F, Friendly M, Kindt R, Legendre P, McGlinn D, et al. vegan: Community Ecology Package. R package version 2.5-6. 2019.
56. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, et al. Software for computing and annotating genomic ranges. *PLoS Comput Biol*. 2013;9(8):e1003118. Epub 2013/08/21. doi: 10.1371/journal.pcbi.1003118. PubMed PMID: 23950696; PubMed Central PMCID: PMC3738458.
57. Gel B, Serra E. karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data. *Bioinformatics*. 2017;33(19):3088-90. Epub 2017/06/03. doi: 10.1093/bioinformatics/btx346. PubMed PMID: 28575171; PubMed Central PMCID: PMC5870550.
58. Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12. 2019.
59. Ralston KS, Solga MD, Mackey-Lawrence NM, Somlata, Bhattacharya A, Petri WA, Jr. Trophocytosis by *Entamoeba histolytica* contributes to cell killing and tissue invasion. *Nature*.

878 2014;508(7497):526-30. doi: 10.1038/nature13242. PubMed PMID: 24717428; PubMed Central
879 PMCID: PMC4006097.
880 60. Miller HW, Suleiman RL, Ralston KS. Trophocytosis by *Entamoeba histolytica* Mediates
881 Acquisition and Display of Human Cell Membrane Proteins and Evasion of Lysis by Human
882 Serum. *MBio*. 2019;10(2). doi: 10.1128/mBio.00068-19. PubMed PMID: 31040235; PubMed
883 Central PMCID: PMC6495370.
884

Figure Legends

Figure 1. RNAi library strategy.

a, The plasmid RNAi library contains random fragments of gDNA cloned into the trigger RNAi plasmid (pTriggerAdaptor). Different plasmid inserts are represented by different colors in this schematic. A heterogeneous population of stably transfected RNAi knockdown mutants can be exposed to selection or screening. To identify mutants that are represented in the population after selection/screening, gDNA is extracted for analysis. gDNA extracted from non-selected amoebae is used as a control. **b**, Schematic representation of the plasmid RNAi library. The trigger plasmid is shown, with different inserts represented by different colors. The “trigger” is a 132 bp fragment of EHI_048600. pTrigger was modified to create pTriggerAdaptor, containing custom Illumina TruSeq adaptor sequences (IA) upstream and downstream of the cloning site to facilitate amplicon sequencing. A single round of PCR is needed to add the remaining Illumina sequences (shown in dark gray) and barcodes necessary for Illumina deep sequencing analysis. **c**, An 812 bp fragment of a BAR/SH3 domain-containing protein (EHI_091530) was inserted into pTrigger with or without custom Illumina TruSeq adaptors flanking the cloning site. The BAR/SH3 domain-containing protein was in the forward orientation and in frame relative to the trigger sequence. Stably transfected heterogeneous mutants were assessed for knockdown of the targeted gene using RT-PCR, with (+) or without (-) reverse transcriptase. GAPDH (EHI_187020) was used as a loading control.

Fig. 2. RNAi library construction.

a, Steps to create the library. *E. histolytica* gDNA was extracted and treated with RNase.

Sonication, followed by gel purification, was used to isolate gDNA fragments. Fragments were end-repaired, A-tailed, and ligated to Y-shaped adaptors. The adaptors contain sequences corresponding to the region upstream and downstream of the cloning site in pTriggerAdaptor. The Y-shaped design ensures that, after PCR to make these sequences double-stranded, each gDNA fragment will be flanked by both the upstream/IA plasmid sequence (represented in black), and the downstream/IA sequence (represented in gray). Finally, the adaptor-ligated gDNA fragments were cloned into pTriggerAdaptor using Gibson cloning. **b – c**, Bioanalyzer traces show appropriate size shift after adaptor ligation, supporting that Y-shaped adaptors were successfully ligated. Example data are shown from optimization experiments that were performed to establish the protocols for library construction. **d**, Gibson cloning and plasmid preps were done *en masse* with pooled plasmids. To check cloning efficiency, individual colonies were obtained and analyzed. Shown are plasmid samples and restriction analysis from the pilot plasmid library preparation. Restriction analysis was performed with restriction enzymes that flank the cloning site (U, uncut; D, digested). Essentially all plasmids that were analyzed contained an insert of the appropriate size range.

Figure 3. The final RNAi library has genome-wide coverage.

a, Nucleotide frequency analysis of the HM1:IMSS reference genome, the pilot and final gDNA fragments, and the pilot and final plasmid libraries. Stacked bar plots show the percentage of each base. The nucleotide composition of the gDNA fragments and the final plasmid library is the same as the genome. **b**, Histograms showing the distribution of fragments sizes for the unique fragments in the pilot and final gDNA fragments, and the

pilot and final plasmid libraries. Size in nucleotides is plotted on the X axis, and probability distribution density is plotted on the Y axis. **c**, Genome coverage plots of the final library, over the five largest contigs in the reference genome. The positions of unique fragments and the depth in fragments overlapping each genomic position are shown. The positions of genes are shown with black and green bars. Fragments that are in the same orientation as genes that are in the forward orientation in the reference genome are shown in black, and fragments that are in the same orientation as genes that are in the reverse orientation in the reference genome are shown in green. **d**, Visual representation of fragment coverage in the final library, over 100 kb of contig DS571145.

Figure 4. Fragment directionality and coverage analysis.

Heat map showing the number of unique fragments per gene in the pilot and final gDNA fragments, and the pilot and final plasmid libraries. The number of unique fragments (Log_2) for each gene are plotted (color value, see legend). Stranded fragments are in the same orientation as genes. Unstranded fragments are the total number of fragments, both in the same orientation as genes and in the opposite orientation as genes.

Figure 5. Identification of slow growth mutants, with phenotypes that are reproducible in independently-generated knockdown mutants.

a, Growth analysis of clonal knockdown mutant lines obtained from screening the heterogeneous library transfectants for growth defects. Amoebae transfected with pTriggerAdaptor (vector control) were used as a negative control, and superoxide dismutase (EHI_159160) knockdown mutants were used as a positive control for slow growth. The library mutants SG1 and SG2 each exhibited a significant growth defect when compared to

vector control transfectants. **b**, RT-PCR analysis demonstrates that the genes corresponding to the plasmid inserts in SG1 and SG2 (EHI_194310 and EHI_007010, respectively), were knocked down. **c**, Knockdown mutants were independently generated by using fragments of these genes that differed from the fragments in the library plasmids. These independent mutants are referred to as SG1i and SG2i. Growth analysis was performed using heterogeneous stable transfectants, and growth mutants exhibited a significant growth defect when compared to vector control. **d**, RT-PCR analysis demonstrates that EHI_194310 and EHI_007010 were knocked down. **e**, Growth phenotypes in SG1, SG2, SG1i and SG2i. Growth values for each mutant were normalized to vector control transfectants. Mutants exhibited statistically significant growth defects relative to vector control transfectants.

Figure 6. SG1 localizes to the cytoplasm and cell surface, and overexpression of SG1 enhances growth.

Amoebae were stably transfected with a plasmid for expression of full-length FLAG-tagged SG1. Immunofluorescence was used to determine the localization of SG1 in heterogeneous transfectants and imaging flow cytometry was used for analysis. **a**, Localization of SG1 in FLAG-SG1 transfectants (left panel) and control staining of wild-type cells (right panel). Samples were permeabilized prior to antibody staining. Six random cells are shown for each condition. Shown from left to right are bright field images (BF), rabbit anti-FLAG antibody staining (FLAG, red), and DAPI staining (DAPI, blue). The numbers in the BF images indicate the object/image number. **b**, Localization of SG1 in FLAG-SG1 transfectants (left panel) and control staining of wild-type cells (right panel), as in panel A, except samples were not permeabilized. **c**, Histograms showing the intensity of the DAPI staining in images collected

from FLAG-SG1 transfectants (left panel) or wild-type cells (right panel). The mean fluorescence intensity (MFI) is indicated on each histogram. **d**, Growth analysis of heterogeneous transfectants expressing full-length SG1 or a C-terminal SG1 truncation mutant. Amoebae transfected with pEhEx (vector control) were used as control. Expression of full-length SG1 was associated with an increase in growth compared to vector control transfectants, that was statistically significant at days 3 ($p < .01$), 4 ($p < .01$), and 5 ($p < .05$), as indicated. The growth of transfectants expressing truncated SG1 was associated with a statistically significant decrease in growth compared to transfectants expressing full-length SG1 at days 2 ($p < .05$), 3 ($p < .05$), 4 ($p < .01$), and 5 ($p < .01$). There was no significant difference between the growth of transfectants expressing truncated SG1 and vector control transfectants at any time point.

Figure 7. SG2 localizes to the cytoplasm.

Amoebae were stably transfected with a plasmid for expression of full-length FLAG-tagged SG2. Immunofluorescence was used to determine the localization of SG2 in heterogeneous transfectants and imaging flow cytometry was used for analysis. **a**, Localization of SG2 in FLAG-SG2 transfectants (left panel) and control staining of wild-type cells (right panel). Samples were permeabilized prior to antibody staining. Six random cells are shown for each condition. Shown from left to right are bright field images (BF), mouse anti-FLAG antibody staining (FLAG, red), and DAPI staining (DAPI, blue). The numbers in the BF images indicate the object/image number. **b**, Histograms showing the intensity of the DAPI staining in images collected from FLAG-SG2 transfectants (left panel) or wild-type cells (right panel). The mean fluorescence intensity (MFI) is indicated on each histogram. **c**, Colocalization

995 analysis of FLAG and DAPI staining. The percentage of DAPI+/FLAG+ images with
996 colocalization of the two markers are indicated.

997 **Table Legends**

998 **Table 1. Library coverage analysis.**

999 Analysis of coverage in the pilot and final gDNA fragments, and the pilot and final plasmid
1000 libraries. Genomic coverage (reported as bp covered, forward, reverse, and unstranded)
1001 was calculated using fragments of the appropriate orientation, inferred from mapped reads
1002 and the *coverage* function in the GenomicRanges R/Bioconductor package. The total
1003 number of covered bp are indicated, and the corresponding percentage of the HM1:IMSS
1004 reference genome that this represents. Forward fragments are in the same orientation as
1005 genes that are in the forward orientation in the reference genome. Reverse fragments are
1006 in the same orientation as genes that are in the reverse orientation in the reference
1007 genome. Stranded fragments are in the same orientation as genes, and are the combined
1008 total of both forward and reverse fragments. Unstranded fragments are the total number of
1009 fragments, both in the same orientation as genes in the reference genome and in the
1010 opposite orientation as genes. Genes that are targeted are those with at least one unique
1011 fragment with greater than or equal to 27nt that overlaps the gene. Genes that are missed
1012 are those that do not fit the criteria for targeted genes. Genes that are targeted by multiple
1013 fragments are those with two or more unique fragments. Counts were calculated using the
1014 countOverlaps function in the GenomicRanges package and annotation from AmoebaDB.
1015 The number of unique fragments is the total number of unique fragments in each sample.

1016 **Table 2. Identified slow growth mutants.**

1017 Summary of growth phenotypes of SG1 – SG12 slow growth mutants, and analysis of the
1018 sequences present in each corresponding library plasmid. Growth values represent cell

1019 numbers normalized to vector control transfectants on day 4 of growth assays. The
 1020 corresponding raw data growth assay data are found in Fig. 5a and Fig. S5a, c, e). Mutants
 1021 exhibited statistically significant growth defects relative to vector control transfectants; *p*-
 1022 values from day 4 are shown. The insert sizes are shown in bp. Insert directionality relative
 1023 to the corresponding coding sequence in the annotated genome is shown. Insert frame
 1024 relative to the trigger sequence in the pTriggerAdaptor is shown. The accession numbers for
 1025 coding sequences that inserts correspond to are indicated, with available annotation
 1026 information and GO terms for each gene (NA, not applicable). Predicted roles in metabolic
 1027 pathways are shown; genes that are predicted to function in more than one metabolic
 1028 pathway are indicated as “several.” These predictions are based on data from KEGG
 1029 Metabolic Pathways (<https://www.kegg.jp>), the MetaCyc Metabolic Pathway Database [42],
 1030 and Chemical Entities of Biological Interest (ChEBI) database [43].

1031 **Supplementary Figure Legends**

1032 **Figure S1. Preparation of RNA-free gDNA from *E. histolytica*.**

1033 Gel electrophoresis analysis of gDNA extracted using the Wizard gDNA extraction kit (Promega),
 1034 Quick-DNA miniprep kit (Zymo), and CTAB extraction. **a**, gDNA isolated using the Wizard kit had
 1035 no apparent RNA contamination, and the gDNA appeared to be of high quality. **b**, gDNA
 1036 isolated using the Quick-DNA kit or CTAB was contaminated with RNA. RNA contamination was
 1037 removed by treatment with RNaseI and subsequent purification. **c**, Bioanalyzer traces of pilot
 1038 and final gDNA samples, after fragmentation and size selection.

1039 **Figure S2. Fragment Mapping Analysis.**

1040 Example view of mapped genomic fragments (“intervals”) represented in the final plasmid
 1041 library. For comparison, the mapped paired end reads that give rise to each fragment are
 1042 shown below each fragment. Shown are results from final plasmid batch two, sequencing
 1043 replicate one, mapped to contig DS571153.

1044 **Figure S3. Appropriate sequencing depth and lack of bias during library construction.**

1045 **a**, Dinucleotide frequency analysis of the HM1:IMSS reference genome, the pilot and final gDNA
 1046 fragments, and the pilot and final plasmid libraries. Stacked bar plots show the percentage of
 1047 each dinucleotide. The dinucleotide composition of the gDNA fragments and the final plasmid
 1048 library is the same as the genome. **b – c**, Rarefaction curves for pilot (panel b) and final (panel c)
 1049 samples. gDNA fragment samples are shown in grey and plasmid samples are shown in orange.
 1050 The number of fragments detected with increasing sequence reads shows if sequencing was
 1051 performed to saturation. Three sequencing replicates are shown for pilot gDNA samples and
 1052 three sequencing replicates are shown for pilot plasmid samples. Three sequencing replicates

are shown for final gDNA samples and three sequencing replicates are shown for each of four batches of final plasmid samples.

Figure S4. Reproducible fragment and read counts from biological and technical replicates.

“Batches” of the final plasmid library were cloned on different days, and represent biological replicates. “Reps” correspond to independently prepared sequencing preparations, and represent technical replicates. **a**, Box plot of read counts per fragment in plasmid samples, with pilot plasmids in orange and final plasmids in grey. Log₂ read counts are shown; outliers (outside of 2nd and 98th percentile) are plotted as points, and the box represents the 25th, and 75th percentile with median indicated as a bold line. Most fragments were represented by multiple sequenced reads. **b**, Stacked bar plots of the total number of fragments detected per sample shows that replicates are similar to each other in the number of fragments identified and that roughly equal numbers of forward and reverse fragments were produced consistently. Forward fragments are in the same orientation as genes that are in the forward orientation in the reference genome. Reverse fragments are in the same orientation as genes that are in the reverse orientation in the reference genome.

Figure S5. Annotated genes that were missed or were least covered by sequencing reads.

Heat map showing the number of unique fragments per gene, for the 50 least covered genes in the pilot and final gDNA fragments, and the pilot and final plasmid libraries. The color intensity indicates Log₂ fragment coverage, with dark blue indicating no coverage. Stranded fragments are in the same orientation as genes. Unstranded fragments are the total number of fragments, both in the same orientation as genes and in the opposite orientation as genes.

Figure S6. Clonal transfectants contain only one library plasmid.

SG1 gDNA was extracted using the Quick-DNA miniprep kit and PCR amplified using the CS5' and CS3' primers that sit in the pTriggerAdaptor backbone. Sanger sequencing was performed using the RNAi Sequencing Library F primer. Adaptor 2 starts at the "GGGG" series of nucleotides, and upstream of this is the SG1 (EHI_194310) sequence. Noncompeting peaks in the chromatogram suggest that there is one unique genome fragment present in this mutant.

Figure S7. Identification of slow growing RNAi knockdown mutants.

Growth analysis of mutants SG1 – SG12. **a, c, e**, Growth analysis demonstrates that selected clonal knockdown mutant lines have significant growth defects compared to vector control transfectants. **b, d, f**, Growth was normalized and compared to vector control transfectants on each day. Mutants exhibited statistically significant growth defects relative to vector control transfectants.

Figure S8. Gating scheme for imaging flow cytometry analysis.

Shown is the gating strategy that was used to analyze imaging flow cytometry data, with the percentage of gated events, and number of gated events, shown below each plot. This example illustrates the gating of the wild-type sample shown in Figure 7. 10,000 events were collected. **a**, In-focus events were gated using a gradient of brightfield (BF). **b**, Events gated in panel a were refined to remove images containing more than one amoeba, by examining the area and the aspect ratio of the object(s) masked in the brightfield image. **c**, Events gated in panel b were refined to remove images that contained saturation in the FLAG channel (channel 11), by examining the raw max pixel intensity (i.e., the intensity of the brightest pixel in the image). **d**, Events gated in panel c as "unsaturated" were further examined to identify images that contained both FLAG and DAPI signal, by examining the

1097 intensity of the object masked in the DAPI and FLAG channels. **e**, Events gated in panel d as
1098 “+DAPI/FLAG” were further examined to characterize the degree of colocalization (bright
1099 detail similarity) between the DAPI and FLAG signals.

1100 **Supplementary Table Legends**

1101 **Table S1. Sequencing and fragment count statistics.**

1102 Total number of paired reads mapping to the same contig (mappedPairs) and the number of
1103 fragments inferred from these mapped pairs for each sample. Reads were mapped with bwa
1104 mem, and processed from the resulting SAM formatted file using a custom Python script.
1105 Three sequencing replicates were performed for pilot gDNA samples and three sequencing
1106 replicates were performed for pilot plasmid samples. Three sequencing replicates were
1107 performed for final gDNA samples and three sequencing replicates were performed for each of
1108 four batches of final plasmid samples.

1109 **Table S2. Expression data for annotated genes that were missing in the final plasmid library.**

1110 Available empirical expression data for genes that were missing in the final plasmid library
1111 (genes that are represented in blue in Fig. S3). Accession numbers, annotation information, and
1112 the number of paralogs in the reference genome are indicated. Presence (+) or absence (-) in
1113 gDNA and plasmid datasets is shown. Gene expression from available RNAseq datasets [44, 45]
1114 is indicated, as the FPKM + 1 value. The highest value for FPKM + 1 for each gene is shown. The
1115 total number of spectra that have been identified in proteomics studies is indicated.

1116 **Table S3. Expression data for representative genes present in the final plasmid library.**

1117 To provide a frame of reference for the expression data in Table S2, shown are the available
1118 empirical expression data for 10 random, representative genes that were present in the final
1119 plasmid library. Accession numbers, annotation information, and the number of paralogs in the
1120 reference genome are indicated. Presence (+) or absence (-) in gDNA and plasmid datasets is
1121 shown. Gene expression from available RNAseq datasets [44, 45] is indicated, as the FPKM + 1

1122 value. The highest value for FPKM + 1 for each gene is shown. The total number of spectra that
1123 have been identified in proteomics studies is indicated.

1124 **Table S4. Primer sequences.**

1125 Sequences of the primers used to generate and sequence plasmids, perform RT-PCR, and
1126 create the plasmid RNAi library.

Figure 4

Table 1

	Pilot		Final	
	gDNA	Plasmid	gDNA	Plasmid
Covered bp, forward	19961090	93257	20500538	19730276
Covered %, forward	96.0	0.5	98.6	94.9
Covered bp, reverse	19949512	99274	20499865	19734222
Covered %, reverse	96.0	0.5	98.6	94.9
Covered bp, unstranded	20401392	191674	20571421	20225883
Covered %, unstranded	98.1	0.9	98.9	97.2
Genes targeted, stranded	8299	152	8310	8302
Genes missed, stranded	34	8181	23	31
Mean fragments per gene, stranded	21	0	59.2	23.3
Genes targeted by multiple fragments, stranded	8270	54	8308	8276
Genes targeted, unstranded	8310	305	8310	8307
Genes missed, unstranded	23	8028	23	26
Mean fragments per gene, unstranded	42.9	0.1	119.9	47.2
Genes targeted by multiple fragments, unstranded	8307	111	8310	8301
Number of unique fragments	537066	621	1509696	489981

Table 2

Name	Normalized growth	p-value	Insert size (bp)	Insert Direction	Insert Frame	Accession	Annotation	Annotated Domains	GO term	Metabolic Pathways
SG1	16.74 +/- 2.17	**	451	Reverse	Out	EHI_194310	Amino acid transporter, putative	Amino acid transporter, transmembrane domain	NA	NA
SG2	22.58 +/- 4.10	**	544	Forward	In	EHI_007010	Hypothetical protein	NA	NA	NA
SG3	72.87 +/- 6.54	*	403	Forward	Out	DS571580	NA	NA	NA	NA
SG4	9.45 +/- 0.78	***	351	Reverse	Out	EHI_110390	Transporter, major facilitator family	MFS transporter superfamily	NA	NA
SG5	14.50 +/- 0.91	***	463	Forward	In	EHI_024220	Hypothetical protein	Importin beta family	Protein import into nucleus	NA
				Forward	In	EHI_160920	Hypothetical protein	Importin beta family	Protein import into nucleus	NA
				Forward	In	EHI_171760	Hypothetical protein	Importin beta family	Obsolete protein import into nucleus, docking	NA
SG6	15.19 +/- 2.23	****	380	Reverse	In	EHI_093960	Pre-mRNA splicing factor, putative	Pre-mRNA-processing factor 6/Prp1/STA1	mRNA splicing, <i>via</i> spliceosome	Several
SG7	19.59 +/- 1.89	***	555	Reverse	In	EHI_009580	Tyrosine kinase, putative	Protein kinase-like domain superfamily	Protein phosphorylation	Several
SG8	65.35 +/- 5.05	***	370	Forward	In	EHI_148960	Hypothetical protein	NA	NA	NA
SG9	11.08 +/- 0.96	***	352	Forward	In	DS571952	NA	NA	NA	NA
SG10	11.45 +/- 1.29	***	425	Forward	In	EHI_069320	C2 domain containing protein	C2 domain	NA	Several
SG11	40.47 +/- 6.77	***	408	Reverse	Out	EHI_098820	Hypothetical protein	Dbl homology (DH) domain; Armadillo-type fold	Regulation of Rho protein signal transduction	NA
SG12	18.09 +/- 1.83	***	322	Reverse	In	DS571214	NA	NA	NA	NA

Figure S2

Table S1

Sample	Mapped Pairs	Fragments
gDNA_Pilot_Rep1	447816	189741
gDNA_Pilot_Rep2	480134	203572
gDNA_Pilot_Rep3	342594	143817
Plasmid_Pilot_Rep1	276964	472
Plasmid_Pilot_Rep2	399114	481
Plasmid_Pilot_Rep3	573080	540
gDNA_Final_Rep1	1317646	522946
gDNA_Final_Rep2	1035946	413343
gDNA_Final_Rep3	1466722	575167
Plasmid_Final_Batch1_Rep1	1500958	92822
Plasmid_Final_Batch1_Rep2	1318560	90347
Plasmid_Final_Batch1_Rep3	1501272	93088
Plasmid_Final_Batch2_Rep1	1457526	126868
Plasmid_Final_Batch2_Rep2	1723194	134349
Plasmid_Final_Batch2_Rep3	1740592	132963
Plasmid_Final_Batch3_Rep1	1467720	129278
Plasmid_Final_Batch3_Rep2	2712002	153399
Plasmid_Final_Batch3_Rep3	2207970	143289
Plasmid_Final_Batch4_Rep1	1588276	40770
Plasmid_Final_Batch4_Rep2	1418664	38870
Plasmid_Final_Batch4_Rep3	2323702	44937

Table S2

Accession	Annotation	Final gDNA	Final Plasmid	Paralogs	RNAseq, FPKM	Proteomics, Spectra
EHI_026690	protein kinase domain containing protein	-	-	-	0.01	2
EHI_093470	hypothetical protein	-	-	-	0.01	-
EHI_142370	hypothetical protein, conserved	-	-	1	0.01	-
EHI_052510	hypothetical protein	-	-	5	0.01	-
EHI_027230	hypothetical protein, conserved	-	-	2	0.01	-
EHI_009130	hypothetical protein	-	-	58	0.01	-
EHI_065120	hypothetical protein, conserved	-	-	1	0.01	-
EHI_073780	DNAJ homolog subfamily A member 2, putative	-	-	2	0.01	-
EHI_167840	WH2 motif domain containing protein	-	-	-	0.01	-
EHI_149330	hypothetical protein, conserved	-	-	2	0.01	-
EHI_162670	hypothetical protein	-	-	-	0.01	-
EHI_130360	modulator of drug activity B homolog, putative	-	-	-	0.01	-
EHI_126760	hypothetical protein	-	-	-	0.01	-
EHI_008920	hypothetical protein	-	-	4	0.01	-
EHI_040950	hypothetical protein	-	-	1	0.01	-
EHI_185010	ribosomal protein L10, putative	-	-	2	0.17	1
EHI_046900	4-alpha-glucanotransferase, putative	-	-	1	0.01	-
EHI_115050	protein kinase, putative	-	-	58	0.01	-
EHI_093460	hypothetical protein	-	-	-	0.01	-
EHI_200340	hypothetical protein	-	-	-	0.01	-
EHI_159040	plasma membrane calcium ion-transporting ATPase, putative	-	-	6	0.01	-
EHI_077770	UDP-glucose:glyco protein glucosyltransferase 1 precursor, putative	-	-	-	0.1	-
EHI_157570	tRNA-Asp (anticodon: GTC)	+	-	-	0.5	-
EHI_087110	hypothetical protein, conserved	+	-	3	432.1	-
EHI_153620	prolyl oligopeptidase family protein	+	-	2	0.05	-
EHI_157670	hypothetical protein	+	-	4	0.56	-

Table S3

Accession	Annotation	Final gDNA	Final Plasmid	Paralogs	RNAseq, FPKM	Proteomics, Spectra
EHI_148050	hypothetical protein, conserved	+	+	-	169.21	22
EHI_148280	p21-activated kinase	+	+	1	404.02	28
EHI_148450	hypothetical protein	+	+	-	17.41	-
EHI_148490	hypothetical protein, conserved	+	+	-	7.62	-
EHI_148550	protein tyrosine kinase domain-containing protein	+	+	13	3.55	-
EHI_148680	hypothetical protein, conserved	+	+	-	18.06	7
EHI_148770	hypothetical protein, conserved	+	+	-	7.66	4
EHI_148840	RhoGAP domain containing protein	+	+	-	16.71	-
EHI_148870	hypothetical protein	+	+	-	38.06	4
EHI_149020	hypothetical protein	+	+	-	3.46	-

Table S4

Primer	Purpose	Sequence
BAR_1FF_F	Cloning	TTAAAAACAAAAATTGCAGCATCAACGCCACCAGATGCAGGAAGATCATCA
BAR_1FF_R	Cloning	GTTTAAAAAGAAGAGTTCAACTCGAGCCCCTCCACTCCACCAATCACCT
BAR_RTPCR_F	RT-PCR	AGGCTTGTTGAGGCATGTACTA
BAR_RTPCR_R	RT-PCR	AAGTTCTCCACTCCACCAATCA
MSP1_1FF_F	Cloning	TTGCAGCATCAACGCCCGGGAATAATCAGAAACGAAATATTTTGG
MSP1_OFF_F	Cloning	AAAGAAGAGTTCAACTCGAGACTAGATGAAAAACATCTTGAATCTT
MSP1_RTPCR_F	RT-PCR	GGTGAGACTCAAGCAAGGGG
MSP1_RTPCR_R	RT-PCR	GGCCATTCTTCTACTTCGCCA
Adaptor1primer_F	Library construction	ACACTCTTTCCTACACGAC
Adaptor2primer_R	Library construction	GTGACTGGAGTTCAGACGTGT
SG0_F	Cloning	TTAAAAACAAAAATTGCAGCATCAACGCCCATGTCTTCCAATTACCAC
SG0_R	Cloning	GTTTAAAAAGAAGAGTTCAACTCGAGCCCTTGAGGGGAAAAGTGAA
SG1i_F	Cloning	TTAAAAACAAAAATTGCAGCATCAACGCCCGTGATGATACTTCTGTCTCTAAC
SG1i_R	Cloning	GTTTAAAAAGAAGAGTTCAACTCGAGCCCCGATACAACGCTCAGTATCTC
SG2i_F	Cloning	TTAAAAACAAAAATTGCAGCATCAACGCCCCATTACCACATTAAGTTCTTC
SG2i_R	Cloning	GTTTAAAAAGAAGAGTTCAACTCGAGCCCGGATAAACAAGAACTAAGTTTTG
SG0_RTPCR_F	RT-PCR	GCTCTTGAGCCTCATATTAGT
SG0_RTPCR_R	RT-PCR	CAACGAACTTCCAGTTGACTAC
SG1_RTPCR_F	RT-PCR	GGAGATACTGAGCGTTGTATCG
SG1_RTPCR_R	RT-PCR	GCATACCACTGTGTTTCTCC
SG2_RTPCR_F	RT-PCR	CATGCCTCACCACATTCACT
SG2_RTPCR_R	RT-PCR	ACCAAACCTCCCATCCTTCAA
GAPDH_RTPCR_F	RT-PCR	CGTCCACAGACAATTCGAAGGAAC
GAPDH_RTPCR_R	RT-PCR	AAGGCAGTTGGTTGTGCATGA
CS5'_F	Sanger sequencing	TCAGTCTTACCACGTCATAAAGT
CS3'_R	Sanger sequencing	TGCAAGAAGATGTTACAAAGCA
LibraryRNAiSeq_F	Sanger sequencing	ACACTCTTTCCTACACGACG
LibraryRNAiSeq_R	Sanger sequencing	GTGACTGGAGTTCAGACGTGT